• In February 2026, Lazard, Inc. added John Koski and Rob Lowe as Managing Directors in its New York Healthcare Group, bringing experience across payors, providers, distributors, and healthcare–technology transactions from roles at Allen & Co. and Citi.
• Around the same time, Lazard reported quarterly results with revenue growth but pressure on margins and earnings, prompting investors to weigh expansion efforts against profitability trends and insider share sales.
• Next, we’ll examine how Lazard’s revenue growth alongside margin pressure may reshape the existing investment narrative and risk–reward balance.

This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

Lazard Investment Narrative Recap

To own Lazard, you need to be comfortable with a fee-based advisory and asset management firm that is investing in senior talent while margins are under pressure. The latest quarter showed revenue growth but weaker profitability, so the key near term debate is whether these hires and global build outs eventually support earnings or simply add to costs. Insider share sales and a high debt load remain important near term risk flags. The February healthcare hires do not materially change that picture yet.

The recent addition of John Koski and Rob Lowe to Lazard’s New York Healthcare Group fits into a broader build out of sector specialists after prior healthcare and sponsors hires. This hiring push is a clear example of the firm leaning into experienced rainmakers as a potential catalyst for future advisory revenue, but it also ties directly into the current concern that rising compensation and investment in new teams could keep net margins under pressure in the short term.

Yet while Lazard is investing in high profile healthcare bankers, investors should also be aware that...

Lazard's narrative projects $4.2 billion revenue and $620.0 million earnings by 2028. This requires 11.3% yearly revenue growth and an earnings increase of about $317.5 million from $302.5 million today.

Uncover how Lazard's forecasts yield a $58.17 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts expected Lazard’s revenue to reach about US$4.1 billion and earnings around US$687.0 million, yet they still worried about fee pressure and talent dependence; this new hiring push could either ease those concerns or deepen them, so it is worth comparing how your view differs from theirs.

Explore 4 other fair value estimates on Lazard - why the stock might be worth as much as 77% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lazard research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Lazard research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lazard's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.